Browse > Article
http://dx.doi.org/10.15207/JKCS.2019.10.1.285

Study on the Effects of Phenyldiazenylanilines on the Activation of Arylhydrocarbon Receptor  

Lee, Hyosung (School of Food and Pharmaceutical Science & Engineering, Seowon University)
Publication Information
Journal of the Korea Convergence Society / v.10, no.1, 2019 , pp. 285-290 More about this Journal
Abstract
AHR regulates the expression of xenobiotics metabolizing enzymes (XMEs) as a transcription fact upon binding of ligands that are mainly aryl hydrocarbons. The role of AHR in human physiology has been intensively investigated for the past decades, however our understanding on AHR yet to be elucidated largely due to the lack of proper chemical agents. It has been demonstrated that AHR correlates to pathogenesis for some diseases in recent studies suggesting that the study on the AHR may provide a valid therapeutic target. Classical antagonists in current use are reported to be partially agonistic whereas a pure antagonist is yet to be found. In this study, phenyldiazenylaniline has been designed based on the structure of two known AHR antagonist, Resveratrol and CH223191. The derivatives of phenyldiazenylaniline have been prepared and subjected to assessment as an AHR antagonist in order to optimize the AHR antagonistic activity of the designed structure by means of convergence study of organic synthesis and molecular biology.
Keywords
AHR (aryl hydrocarbon receptor); antagonist; phenyldiazenylanline; proper chemical agent; phenyldiazenylaniline; convergence study of chemical structure and biological activity;
Citations & Related Records
연도 인용수 순위
  • Reference
1 J. Reiners, Jr., R. Clift & P. Mathieu. (1999). Suppression of cell cycle progression by flavonoids: dependence on the aryl hydrocarbon receptor, Carcinogenesis, 20(8), 561-1566..
2 E. Y. Choi, H. Lee, R. W. Dingle, K. B. Kim & H. I. Swanson. (2012). AHR-based Therapeutic Agents, Molecular and Cellular Pharmacology, 4(2), 53-60.
3 S. Kronenberg, C. Esser, & C. Carlberg. (2000). An aryl hydrocarbon receptor conformation acts as the functional core of nuclear dioxin signaling, Nucleic Acids Research. 28(12), 2286-2291.   DOI
4 H. T. Clarke, W. R. Kirner. (1922). Methyl Red, Organic Synthesis, 2, 47-50.   DOI
5 K. M. Burbach, A. Poland & C. A. Bradfield. (1992). Cloning of the Ah-receptor cDNA reveals a distinctive ligand-activated transcription factor, Proceedings of the National Academy of Sciences, 89(17), 8185-8189.
6 A. B. Okey, D. S. Riddick & P. A. Harper. (1994). Molecular biology of the aromatic hydrocarbon (dioxin) receptor, Trends in Pharmacological Sciences, 15(7), 226-232.   DOI
7 Ma C., Marlowe J.L., Puga A. (2009) The aryl hydrocarbon receptor at the crossroads of multiple signaling pathways. In: Luch A. (eds) Molecular, Clinical and Environmental Toxicology. Experientia Supplementum, Basel, Birkhauser. DOI : https://doi.org/10.1007/978-3-7643-8336-7_9
8 F. Yang & D. Bleich. (2004). Transcriptional regulation of cyclooxygenase-2 gene in pancreatic beta-cells, Journal of Biological Chemistry, 279(34), 35403-35411.   DOI
9 E. J. Choi, D. G. Toscano, J. A. Ryan, N. Riedel & W. A. Toscano, Jr. (1991). Dioxin induces transforming growth factor-alpha in human keratinocytes, The Journal of Biological Chemistry, 266(15), 9591-9597.   DOI
10 A. Levine-Fridman, L. Chen & C. J. Elferink. (2004). Cytochrome P4501A1 promotes G1 phase cell cycle progression by controlling aryl hydrocarbon receptor activity, Molecular Pharmacology, 65(2), 461-469.   DOI
11 J. Guo, M. Sartor, S. Karyala, M. Medvedovic, S. Kann, A. Puga, P. Ryan & C. R. Tomlinson. (2004). Expression of genes in the TGF-beta signaling pathway is significantly deregulated in smooth muscle cells from aorta of aryl hydrocarbon receptor knockout mice, Toxicology and Applied Pharmacology, 194(1), 79-89.   DOI
12 Y. F. Lu, M. Santostefano, B. D. Cunningham, M. D. (1996). Threadgill and S. Safe, Substituted flavones as aryl hydrocarbon receptor agonists and antagonists, Biochemical Pharmacology, 51(8), 1077-1087.   DOI
13 J. E. Lee & S. Safe. (2000). 3',4'-dimethoxyflavone as an aryl hydrocarbon receptor antagonist in human breast cancer cells, Toxicological Sciences, 58(2), 235-242.   DOI
14 A. Y. Berman, R. A. Metechin, M. Y. Wiesenfeld, M. K. Holz. (2017). The therapeutic potential of resvertrol: a review of clinical trials, NPJ Precision Oncology, 1(1), 35-43.   DOI
15 S. H. Kim, E. C. Henry, D. K. Kim, Y. H. Kim, K. J. Shin, M. S. Han, T. G. Lee, J. K. Kang, T. A. Gasiewicz, S. H. Ryu, P. G. Suh. (2006). Novel compound 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) prevents 2,3,7,8-TCDD-induced toxicity by antagonizing the aryl hydrocarbon receptor, Molecular Pharmacology, 69(6), 1871-1878.   DOI